Table Of Contents
- Aciphex Price Comparison Table
- Aciphex Information
- Aciphex Ingredients and Composition
- How Does Aciphex Work?
- How To Take Aciphex and Aciphex Dosage and Administration
- If you suspect a Aciphex Overdose
- Aciphex Pill Identification / ID and Appearance
- Aciphex Side Effects
- Aciphex Precautions and Contraindications
- Contraindications to Aciphex
- Aciphex Drug Interactions
- Storing Aciphex
- Credits for Aciphex Information
Brand names: Aciphex, Pariet
Aciphex Price Comparison Table
| Product | Qty | Medical Fees & Shipping | Price/ Qty | Price | Click to Order |
|---|---|---|---|---|---|
| Aciphex 20mg | 30 | $10.95 | $2.15ea | $64.62 | Buy from PharmaWebCanada |
| Aciphex 20mg | 30 | $15.00 | $5.61ea | $168.40 | Buy from RxPayouts |
| Aciphex 20mg | 30 | $18.00 | $6.13ea | $184.00 | Buy from MPllc |
| Aciphex 20mg | 30 | $18.00 | $6.33ea | $190.00 | Buy from Billing-md |
| Aciphex 20mg | 60 | $15.00 | $5.04ea | $302.40 | Buy from RxPayouts |
| Aciphex 20mg | 60 | $18.00 | $5.65ea | $339.00 | Buy from Billing-md |
| Aciphex 20mg | 60 | $18.00 | $5.65ea | $339.00 | Buy from MPllc |
| Aciphex 20mg | 90 | $10.95 | $2.15ea | $193.85 | Buy from PharmaWebCanada |
| Aciphex 20mg | 90 | $15.00 | $4.77ea | $429.11 | Buy from RxPayouts |
| Aciphex 20mg | 90 | $18.00 | $5.27ea | $474.00 | Buy from Billing-md |
| Aciphex 20mg | 90 | Free Shipping | $5.31ea | $478.00 | Buy from MPllc |
Aciphex 20mg| Product | Qty | Medical Fees & Shipping | Price/ Qty | Price | Click to Order |
|---|---|---|---|---|---|
| Aciphex 10mg | 30 | $10.95 | $0.77ea | $23.05 | Buy from PharmaWebCanada |
| Aciphex 10mg | 30 | $18.00 | $6.50ea | $195.00 | Buy from MPllc |
| Aciphex 10mg | 90 | $10.95 | $0.77ea | $69.14 | Buy from PharmaWebCanada |
When buying online you have to be aware of a few things:
- All our pharmacies offer free consultation by licensed Doctors, were required.
- Some Pharmacies offer next Day Shipping or Saturday Shipping. This may cost extra.
- All shipping costs are shown before you place your order
- Private & Confidential Service, Secure Online Order Form.
Aciphex Information
Brand Name: Aciphex
Generic Name: Rabeprazole Sodium
Other Names: Medication Code E243, Pariet
Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)
Aciphex is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered.
Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)
Aciphex is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD maintenance).
Healing of Duodenal Ulcers
Aciphex is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks.
Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome
Aciphex is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.
Aciphex Ingredients and Composition
The active ingredient in Aciphex Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole sodium salt. It has an empirical formula of C18H20N3NaO3S and a molecular weight of 381.43. Rabeprazole sodium, the active ingredient in Aciphex, is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions.
Aciphex is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium. Inactive ingredients are mannitol, hydroxypropyl cellulose, magnesium oxide, low-substituted hydroxypropyl cellulose, magnesium stearate, ethylcellulose, hydroxypropyl methylcellulose phthalate, diacetylated monoglycerides, talc, titanium dioxide, carnauba wax, and ferric oxide (yellow) as a coloring agent.
How Does Aciphex Work?
Pharmacokinetics and Metabolism
Aciphex delayed-release tablets are enteric-coated to allow rabeprazole sodium, which is acid labile, to pass through the stomach relatively intact. After oral administration of 20 mg Aciphex , peak plasma concentrations (Cmax) of rabeprazole occur over a range of 2.0 to 5.0 hours (Tmax). The rabeprazole Cmax and AUC are linear over an oral dose range of 10 mg to 40 mg. There is no appreciable accumulation when doses of 10 mg to 40 mg are administered every 24 hours; the pharmacokinetics of rabeprazole are not altered by multiple dosing. The plasma half-life ranges from 1 to 2 hours.
How To Take Aciphex and Aciphex Dosage and Administration
Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)
The recommended adult oral dose is one Aciphex 20 mg delayed-release tablet to be taken once daily for four to eight weeks. For those patients who have not healed after 8 weeks of treatment, an additional 8-week course may be considered.
Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD Maintenance)
The recommended adult oral dose is one Aciphex 20 mg delayed-release tablet to be taken once daily.
Healing of Duodenal Ulcers
The recommended adult oral dose is one Aciphex 20 mg delayed-release tablet to be taken once daily after the morning meal for a period up to four weeks. Most patients with duodenal ulcer heal within four weeks. A few patients may require additional therapy to achieve healing.
Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
The Aciphex dosage in patients with pathologic hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered. Some patients with Zollinger-Ellison syndrome have been treated continuously with Aciphex for up to one year.
No Aciphex dosage adjustment is necessary in elderly patients, in patients with renal disease or in patients with mild to moderate hepatic impairment. Administration of rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Due to the lack of clinical data on rabeprazole in patients with severe hepatic impairment, caution should be exercised in those patients.
Aciphex tablets should be swallowed whole. The tablets should not be chewed, crushed, or split.
If you suspect a Aciphex Overdose
Because strategies for the management of Aciphex overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug. There has been no experience with large overdoses with rabeprazole. Seven reports of accidental overdosage with rabeprazole have been received. The maximum reported overdose was 80 mg. There were no clinical signs or symptoms associated with any reported Aciphex overdose. Patients with Zollinger-Ellison syndrome have been treated with up to 120 mg rabeprazole QD. No specific antidote for rabeprazole is known. Rabeprazole is extensively protein bound and is not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.
Single oral doses of rabeprazole at 786 mg/kg and 1024 mg/kg were lethal to mice and rats, respectively. The single oral dose of 2000 mg/kg was not lethal to dogs. The major symptoms of acute toxicity were hypoactivity, labored respiration, lateral or prone position and convulsion in mice and rats and watery diarrhea, tremor, convulsion and coma in dogs.
Aciphex Pill Identification / ID and Appearance
Aciphex 20 mg is supplied as delayed-release light yellow enteric-coated tablets.
The medication code number (E243) is imprinted on one side.
Bottles of 30 (NDC# 62856-243-30)
Unit Dose Blisters Package of 100 (10 x 10) (NDC# 62856-243-41)
Aciphex Side Effects
Worldwide, over 2900 patients have been treated with Aciphex in Phase II-III clinical trials involving various dosages and durations of treatment. In general, rabeprazole treatment has been well-tolerated in both short-term and long-term trials. The adverse events rates were generally similar between the 10 and 20 mg doses.
Incidence in Controlled North American and European Clinical Trials
In an analysis of adverse events assessed as possibly or probably related to treatment appearing in greater than 1% of ACIPHEX TM patients and appearing with greater frequency than placebo in controlled North American and European trials, the incidence of headache was 2.4% (n= 1552) for ACIPHEXTM versus 1.6% (n= 258) for placebo.
In short and long- term studies, the following adverse events, regardless of causality, were reported in Aciphex-treated patients. Rare events are those reported in ≤1/1000 patients.
Body as a Whole:
- asthenia
- fever
- allergic reaction
- chills
- malaise
- chest pain substernal
- neck rigidity
- photosensitivity reaction. Rare: abdomen enlarged
- face edema
- hangover effect
Cardiovascular System:
- hypertension
- myocardial infarct
- electrocardiogram abnormal
- migraine
- syncope
- angina pectoris
- bundle branch block
- palpitation
- sinus bradycardia
- tachycardia. Rare: bradycardia
- pulmonary embolus
- supraventricular tachycardia
- thrombophlebitis
- vasodilation
- QTC prolongation and ventricular tachycardia
Digestive System:
- diarrhea
- nausea
- abdominal pain
- vomiting
- dyspepsia
- flatulence
- constipation
- dry mouth
- eructation
- gastroenteritis
- rectal hemorrhage
- melena
- anorexia
- cholelithiasis
- mouth ulceration
- stomatitis
- dysphagia
- gingivitis
- cholecystitis
- increased appetite
- abnormal stools
- colitis
- esophagitis
- glossitis
- pancreatitis
- proctitis. Rare: bloody diarrhea
- cholangitis
- duodenitis
- gastrointestinal hemorrhage
- hepatic encephalopathy
- hepatitis
- hepatoma
- liver fatty deposit
- salivary gland enlargement
- thirst.
Endocrine System:
- hyperthyroidism
- hypothyroidism.
Hemic & Lymphatic System:
- anemia
- ecchymosis
- lymphadenopathy
- hypochromic anemia.
Metabolic & Nutritional Disorders:
- peripheral edema
- edema
- weight gain
- gout
- dehydration
- weight loss
Musculo-Skeletal System:
- myalgia
- arthritis
- leg cramps
- bone pain
- arthrosis
- bursitis
Musculo-Skeletal System (rare):
- twitching
Nervous System:
- insomnia
- anxiety
- dizziness
- depression
- nervousness
- somnolence
- hypertonia
- neuralgia
- vertigo
- convulsion
- abnormal dreams
- libido decreased
- neuropathy
- paresthesia
- tremor
Nervous System (rare):
- agitation
- amnesia
- confusion
- extrapyramidal syndrome
- hyperkinesia
Respiratory System:
- dyspnea
- asthma
- epistaxis
- laryngitis
- hiccup
- hyperventilation.
Respiratory System (rare):
- apnea
- hypoventilation.
Skin and Appendages:
- rash
- pruritus
- sweating
- urticaria
- alopecia
Skin and Appendages (rare):
- dry skin
- herpes zoster
- psoriasis
- skin discoloration
Special Senses:
- cataract
- amblyopia
- glaucoma
- dry eyes
- abnormal vision
- tinnitus
- otitis media
Special Senses (rare):
- corneal opacity
- blurry vision
- diplopia
- deafness
- eye pain
- retinal degeneration
- strabismus
Urogenital System
cystitis, urinary frequency, dysmenorrhea, dysuria, kidney calculus, metrorrhagia, polyuria. Rare: breast enlargement, hematuria, impotence, leukorrhea, menorrhagia, orchitis, urinary incontinence.
As with any drug, you may experience additional Aciphex side effects.
Aciphex Precautions and Contraindications
General
Symptomatic response to therapy with rabeprazole does not preclude the presence of gastric malignancy.
Patients with healed GERD were treated for up to 40 months with Aciphex and monitored with serial gastric biopsies. Patients without H. pylori infection (221 of 326 patients) had no clinically important pathologic changes in the gastric mucosa. Patients with H. pylori infection at baseline (105 of 326 patients) had mild or moderate inflammation in the gastric body or mild inflammation in the gastric antrum. Patients with mild grades of infection or inflammation in the gastric body tended to change to moderate, whereas those graded moderate at baseline tended to remain stable. Patients with mild grades of infection or inflammation in the gastric antrum tended to remain stable. At baseline 8% of patients had atrophy of glands in the gastric body and 15% had atrophy in the gastric antrum. At endpoint, 15% of patients had atrophy of glands in the gastric body and 11% had atrophy in the gastric antrum. Approximately 4% of Aciphex patients had intestinal metaplasia at some point during follow-up, but no consistent changes were seen.
Contraindications to Aciphex
Rabeprazole, the active ingredient in Aciphex, is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles or to any component of the formulation.
Aciphex Drug Interactions
Rabeprazole, the active ingredient of Aciphex, is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system. Studies in healthy subjects have shown that rabeprazole does not have clinically significant interactions with other drugs metabolized by the CYP450 system, such as warfarin and theophylline given as single oral doses, diazepam as a single intravenous dose, and phenytoin given as a single intravenous dose (with supplemental oral dosing). In vitro incubations employing human liver microsomes indicated that rabeprazole inhibited cyclosporin metabolism with an IC50 of 62 micromolar, a concentration that is over 50 times higher than the Cmax in healthy volunteers following 14 days of dosing with 20 mg of rabeprazole. This degree of inhibition is similar to that by omeprazole at equivalent concentrations.
Aciphex produces sustained inhibition of gastric acid secretion. An interaction with compounds which are dependent on gastric pH for absorption may occur due to the magnitude of acid suppression observed with rabeprazole. For example, in normal subjects, co-administration of rabeprazole 20 mg QD resulted in an approximately 30% decrease in the bioavailability of ketoconazole and increases in the AUC and Cmax for digoxin of 19% and 29%, respectively. Therefore, patients may need to be monitored when such drugs are taken concomitantly with rabeprazole. Co-administration of rabeprazole and antacids produced no clinically relevant changes in plasma rabeprazole concentrations.
Storing Aciphex
Store Aciphex at 25°C (77°F); excursions permitted to 15- 30°C (59- 86°F). Protect from moisture.
Credits for Aciphex Information
Aciphex information on this page is copyright by Drug Information at Pharma-Help.com, reprinted with Permission. All Rights Reserved. Other pages with reprint permission include Aciphex.